Anbio Biotechnology, a global medical technology company focused on in vitro diagnostics, has successfully closed its initial public offering of 1,600,000 Class A ordinary shares at a price of $5.00 ...

LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT, LIXTW), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class inhibitor of protein phosphatase 2A ...